AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14563577 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiographic parameters (initial Thrombolysis in Myocardial Infarction flow grade, number of diseased vessels, culprit vessel)
Number of subjects: 302
Study 14563577 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular ejection fraction
Number of subjects: 302
Study 8788351 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention leaflet
Number of subjects: 120
Study 8788351 — intervention group
Group type: COMPARATOR
Intervention: Control leaflet
Number of subjects: 120
Study 1337745 — intervention group
Group type: EXPERIMENTAL
Intervention: nedocromil sodium 2% eyedrops
Number of subjects: 20
Study 1337745 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 6370030 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorprothixene 1 mg/kg i.m.
Number of subjects: 90
Study 6370030 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorprothixene 2 mg/kg orally
Number of subjects: 90
Study 6370030 — intervention group
Group type: COMPARATOR
Intervention: No premedication
Number of subjects: 90
Study 30630465 — intervention group
Group type: EXPERIMENTAL
Intervention: Locking blade nail (LBN)
Number of subjects: 68
Study 30630465 — intervention group
Group type: COMPARATOR
Intervention: Locking plate (PHILOS)
Number of subjects: 68
Study 29189568 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid (TXA)
Number of subjects: 80
Study 29189568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 27087109 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA)
Number of subjects: 307
Study 27087109 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous physical activity (VPA)
Number of subjects: 307
Study 27087109 — intervention group
Group type: EXPERIMENTAL
Intervention: VPA and MVPA
Number of subjects: 307
Study 27087109 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary behavior (SB)
Number of subjects: 307
Study 27087109 — intervention group
Group type: EXPERIMENTAL
Intervention: Substituting 5 min per day of SB, LPA or MPA with 5 min per day of VPA
Number of subjects: 307
Study 27087109 — intervention group
Group type: EXPERIMENTAL
Intervention: Substituting 5 min per day of VPA with SB or LPA
Number of subjects: 307
Study 25096067 — intervention group
Group type: EXPERIMENTAL
Intervention: vemurafenib, 960 mg orally twice daily
Number of subjects: 675
Study 25096067 — intervention group
Group type: COMPARATOR
Intervention: dacarbazine, 1,000 mg/m2 intravenously every 3 weeks
Number of subjects: 675
Study 22419641 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin (4 months)
Number of subjects: 0
Study 22419641 — intervention group
Group type: COMPARATOR
Intervention: Isoniazid (9 months)
Number of subjects: 0
Study 19779355 — intervention group
Group type: EXPERIMENTAL
Intervention: HIVIGLOB/NVP
Number of subjects: 0
Study 19779355 — intervention group
Group type: COMPARATOR
Intervention: HIVNET 012
Number of subjects: 0
Study 18004923 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal information using the illustration catalog and self application by the patient (I+A)
Number of subjects: 150
Study 18004923 — intervention group
Group type: COMPARATOR
Intervention: Verbal information (V)
Number of subjects: 150
Study 18004923 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal information with demonstration on model (M)
Number of subjects: 150
Study 18004923 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal information with demonstration on model and self application by the patient (M+A)
Number of subjects: 150
Study 18004923 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal information using the illustration catalog (I)
Number of subjects: 150
Study 15767288 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 3029
Study 15767288 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol tartrate
Number of subjects: 3029
Study 15767288 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation at baseline
Number of subjects: 3029
Study 15767288 — intervention group
Group type: EXPERIMENTAL
Intervention: New onset atrial fibrillation during follow-up
Number of subjects: 3029
Study 11939810 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% tazarotene gel applied twice daily (T + T)
Number of subjects: 99
Study 11939810 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% tazarotene gel applied once daily and vehicle gel once daily (T + V)
Number of subjects: 99
Study 11939810 — intervention group
Group type: COMPARATOR
Intervention: Vehicle gel applied twice daily (V + V)
Number of subjects: 99
Study 9873966 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask (LMA)
Number of subjects: 20
Study 9873966 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuffed oropharyngeal airway
Number of subjects: 20
Study 9873966 — intervention group
Group type: COMPARATOR
Intervention: Face mask
Number of subjects: 20
Study 8529320 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachial artery pulse amplitudes with progressively compressive forces (0.45‐4.29N)
Number of subjects: 10
Study 8529320 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial artery pulse amplitudes with progressively compressive forces (0.45‐4.29N)
Number of subjects: 10
Study 8529320 — intervention group
Group type: EXPERIMENTAL
Intervention: Applied forces up to 2.18 +/- 0.02N at brachial artery
Number of subjects: 10
Study 8529320 — intervention group
Group type: EXPERIMENTAL
Intervention: Applied forces up to 2.59 +/- 0.02N at radial artery
Number of subjects: 10
Study 8529320 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial artery pulses at and beyond a force of 2.99 +/- 0.01N
Number of subjects: 10
Study 2355823 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphate loading (1000 mg of tribasic sodium phosphate, four times daily for 6 days)
Number of subjects: 7
Study 2355823 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphate loading
Number of subjects: 7
Study 2355823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 122406 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg haloperidol
Number of subjects: 5
Study 122406 — intervention group
Group type: EXPERIMENTAL
Intervention: 88 IU human LH (hLH)
Number of subjects: 5
Study 122406 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolactin plus luteinizing hormone
Number of subjects: 5
Study 122406 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 5
Study 30939483 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors (Canagliflozin, Empagliflozin, Dapagliflozin)
Number of subjects: 0
Study 27921139 — intervention group
Group type: EXPERIMENTAL
Intervention: PCSO-524®
Number of subjects: 144
Study 27921139 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 26469104 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C9*2 and/or *3 genotypes
Number of subjects: 43
Study 26469104 — intervention group
Group type: COMPARATOR
Intervention: CYP2C9*1/*1 genotype (Control)
Number of subjects: 43
Study 23187044 — intervention group
Group type: EXPERIMENTAL
Intervention: Paraffin bath therapy (5 times per week, for 3-week duration)
Number of subjects: 56
Study 23187044 — intervention group
Group type: COMPARATOR
Intervention: Control group (no paraffin bath therapy)
Number of subjects: 56
Study 23187044 — intervention group
Group type: EXPERIMENTAL
Intervention: Paraffin bath therapy
Number of subjects: 56
Study 22025157 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib (150 mg orally once a day) + Placebo
Number of subjects: 172
Study 22025157 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg orally once a day) + R1507 (9 mg/kg weekly)
Number of subjects: 172
Study 22025157 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg orally once a day) + R1507 (16 mg/kg every 3 weeks)
Number of subjects: 172
Study 22025157 — intervention group
Group type: EXPERIMENTAL
Intervention: R1507 (9 mg/kg weekly)
Number of subjects: 172
Study 22025157 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172
Study 18481717 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with He-Ne laser radiation
Number of subjects: 97
Study 18481717 — intervention group
Group type: COMPARATOR
Intervention: Routine western medicine
Number of subjects: 97
Study 16329770 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic dissector
Number of subjects: 120
Study 16329770 — intervention group
Group type: COMPARATOR
Intervention: Conventional method
Number of subjects: 120
Study 12045122 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolastin (60 mg/kg) administered in four infusions at weekly intervals
Number of subjects: 12
Study 10213433 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 microg/mL(‐1) of PPF and 0.5 ng/mL(‐1) of SUF in group I (GI)
Number of subjects: 20
Study 10213433 — intervention group
Group type: COMPARATOR
Intervention: 3 microg/mL(‐1) of PPF and 1 ng/mL(‐1) of SUF in group II (GII)
Number of subjects: 20
Study 7789477 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary LTE4 concentration after returning to Davos from The Netherlands
Number of subjects: 14
Study 7789477 — intervention group
Group type: EXPERIMENTAL
Intervention: PC20FEV1 after returning to Davos from The Netherlands
Number of subjects: 14
Study 7789477 — intervention group
Group type: EXPERIMENTAL
Intervention: FEV1 after returning to Davos from The Netherlands
Number of subjects: 14
Study 2141775 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy
Number of subjects: 26
Study 2141775 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation
Number of subjects: 26
Study 2141775 — intervention group
Group type: COMPARATOR
Intervention: Pentoxifylline
Number of subjects: 26
Study 655282 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (50 mg)
Number of subjects: 0
Study 655282 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (100 mg)
Number of subjects: 0
Study 655282 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 0
Study 28704267 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational intervention
Number of subjects: 263
Study 28704267 — intervention group
Group type: COMPARATOR
Intervention: Control group (self-assessment leaflet)
Number of subjects: 263
Study 29133320 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive 3-week home-based preoperative exercise training programme (R group)
Number of subjects: 90
Study 29133320 — intervention group
Group type: COMPARATOR
Intervention: Usual physical therapy (Control group)
Number of subjects: 90
Study 25922251 — intervention group
Group type: EXPERIMENTAL
Intervention: Dedicated cold snare
Number of subjects: 76
Study 25922251 — intervention group
Group type: COMPARATOR
Intervention: Traditional cold snare
Number of subjects: 76
Study 23629602 — intervention group
Group type: EXPERIMENTAL
Intervention: CTHA/CTAP
Number of subjects: 280
Study 23629602 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 280
Study 21039929 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8% black tea extract (BTE) diet
Number of subjects: 96
Study 21039929 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4% black tea extract (BTE) diet
Number of subjects: 96
Study 21039929 — intervention group
Group type: COMPARATOR
Intervention: Control diet (0% BTE)
Number of subjects: 96
Study 21039929 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro study with BTE
Number of subjects: 96
Study 19253234 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose isotretinoin (>0.5 mg/kg per day)
Number of subjects: 51
Study 19253234 — intervention group
Group type: COMPARATOR
Intervention: Low-dose isotretinoin (<0.5 mg/kg per day)
Number of subjects: 51
Study 17290375 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (morning)
Number of subjects: 0
Study 17290375 — intervention group
Group type: COMPARATOR
Intervention: Placebo (morning)
Number of subjects: 0
Study 15495821 — intervention group
Group type: EXPERIMENTAL
Intervention: Puerarin injection (500 mg per day for 2 weeks)
Number of subjects: 61
Study 15495821 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (Control group)
Number of subjects: 61
Study 11560455 — intervention group
Group type: EXPERIMENTAL
Intervention: bupropion, 300 mg/d
Number of subjects: 784
Study 9783890 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiation therapy
Number of subjects: 960
Study 9783890 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiation therapy
Number of subjects: 960
Study 9783890 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 960
Study 9783890 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose-volume group
Number of subjects: 960
Study 7923670 — intervention group
Group type: EXPERIMENTAL
Intervention: 60-microF capacitors
Number of subjects: 67
Study 7923670 — intervention group
Group type: COMPARATOR
Intervention: 120-microF capacitors
Number of subjects: 67
Study 3169110 — intervention group
Group type: EXPERIMENTAL
Intervention: Cicloprolol 25 mg
Number of subjects: 0
Study 3169110 — intervention group
Group type: EXPERIMENTAL
Intervention: Cicloprolol 50 mg
Number of subjects: 0
Study 3169110 — intervention group
Group type: EXPERIMENTAL
Intervention: Cicloprolol 100 mg
Number of subjects: 0
Study 3169110 — intervention group
Group type: EXPERIMENTAL
Intervention: Cicloprolol (up to 200 mg)
Number of subjects: 0
Study 3169110 — intervention group
Group type: EXPERIMENTAL
Intervention: Cicloprolol
Number of subjects: 0
Study 3169110 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3169110 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg
Number of subjects: 0
Study 3169110 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol 10 mg
Number of subjects: 0
Study 3169110 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 8 mg
Number of subjects: 0
Study 3169110 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenalterol 50 mg
Number of subjects: 0
Study 29601367 — intervention group
Group type: EXPERIMENTAL
Intervention: BrainHQ (8-week, 40-hour program individualized to each patient's performance)
Number of subjects: 264
Study 29601367 — intervention group
Group type: COMPARATOR
Intervention: Active control computer-based crossword puzzles
Number of subjects: 264
Study 29601367 — intervention group
Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 264
Study 27295179 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple P parenting intervention
Number of subjects: 107
Study 26265125 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol treatment (n=1533)
Number of subjects: 2839
Study 26265125 — intervention group
Group type: COMPARATOR
Intervention: Nonmannitol treatment (n=993)
Number of subjects: 2839
Study 26265125 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol treatment in patients with larger baseline hematomas (≥15 mL)
Number of subjects: 2839
Study 26265125 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol treatment
Number of subjects: 2839
Study 23765639 — intervention group
Group type: COMPARATOR
Intervention: Vardenafil (10 mg/day, for 12 weeks)
Number of subjects: 0
Study 23765639 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil or Vardenafil
Number of subjects: 0
Study 21037437 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX)
Number of subjects: 101
Study 21037437 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 19087497 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve-sparing radical hysterectomy (NSRH)
Number of subjects: 44
Study 19087497 — intervention group
Group type: COMPARATOR
Intervention: Conventional radical hysterectomy (CRH)
Number of subjects: 44
Study 15040559 — intervention group
Group type: EXPERIMENTAL
Intervention: AQ/SP
Number of subjects: 265
Study 15040559 — intervention group
Group type: EXPERIMENTAL
Intervention: CQ/SP
Number of subjects: 265
Study 15040559 — intervention group
Group type: EXPERIMENTAL
Intervention: SP
Number of subjects: 265
Study 11848258 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (2 mg) and Indapamide (0.625 mg)
Number of subjects: 471
Study 11848258 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (50 mg)
Number of subjects: 471
Study 11848258 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 471
Study 9544371 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia (Group A)
Number of subjects: 0
Study 9544371 — intervention group
Group type: COMPARATOR
Intervention: Local anesthesia (Group B)
Number of subjects: 0
Study 7851264 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized learning activity packages
Number of subjects: 40
Study 7851264 — intervention group
Group type: COMPARATOR
Intervention: Classroom instruction
Number of subjects: 40
Study 2894399 — intervention group
Group type: EXPERIMENTAL
Intervention: DTP-AC vaccine
Number of subjects: 39
Study 2894399 — intervention group
Group type: COMPARATOR
Intervention: DTP-WC vaccine
Number of subjects: 39
Study 29102669 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of filtered air containing particulate mixture (PM 10, PM 2.5, PM 1.0 and PM 0.5 µm)
Number of subjects: 12
Study 29102669 — intervention group
Group type: COMPARATOR
Intervention: Inhalation of filtered air mixture (control)
Number of subjects: 12
Study 27377521 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-Dose (SID) bowel preparation
Number of subjects: 341
Study 27377521 — intervention group
Group type: COMPARATOR
Intervention: Split-Dose (SPD1) bowel preparation
Number of subjects: 341
Study 27377521 — intervention group
Group type: COMPARATOR
Intervention: Split-Dose (SPD2) bowel preparation
Number of subjects: 341
Study 24526078 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased professional fluoride application (IPFA) programme
Number of subjects: 230
Study 24526078 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-operative caries treatment and prevention (NOCTP) programme
Number of subjects: 230
Study 24526078 — intervention group
Group type: COMPARATOR
Intervention: Regular dental care
Number of subjects: 230
Study 23363790 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy combined with dendritic cell and cytokine-induced killer cell (DC-CIK) immunotherapy
Number of subjects: 60
Study 23363790 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy only
Number of subjects: 60
Study 20502373 — intervention group
Group type: EXPERIMENTAL
Intervention: Transtympanic approach
Number of subjects: 61
Study 20502373 — intervention group
Group type: COMPARATOR
Intervention: Tympanomeatal flap elevation
Number of subjects: 61
Study 17964871 — intervention group
Group type: EXPERIMENTAL
Intervention: standard therapy + granulocyte-colony stimulating factor (5 microg/kg/day for 6 days)
Number of subjects: 24
Study 17964871 — intervention group
Group type: EXPERIMENTAL
Intervention: standard therapy + granulocyte-colony stimulating factor (15 microg/kg/day s.c. for 6 days)
Number of subjects: 24
Study 17964871 — intervention group
Group type: COMPARATOR
Intervention: standard therapy
Number of subjects: 24
Study 17964871 — intervention group
Group type: COMPARATOR
Intervention: healthy donors treated with granulocyte-colony stimulating factor
Number of subjects: 24
Study 17964871 — intervention group
Group type: EXPERIMENTAL
Intervention: granulocyte-colony stimulating factor treatment
Number of subjects: 24
Study 15642561 — intervention group
Group type: EXPERIMENTAL
Intervention: atorvastatin + amlodipine
Number of subjects: 134
Study 15642561 — intervention group
Group type: COMPARATOR
Intervention: atorvastatin + placebo
Number of subjects: 134
Study 11509086 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinpocetine in combination with low‐molecular weight dextran (n = 15)
Number of subjects: 30
Study 11509086 — intervention group
Group type: COMPARATOR
Intervention: Low‐molecular weight dextran alone (n = 15)
Number of subjects: 30
Study 9446908 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of all individuals in a class together with family members of positive cases
Number of subjects: 738
Study 9446908 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of only egg positive cases
Number of subjects: 738
Study 7916157 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose neuroleptic treatment (above 375 mg equivalent of chlorpromazine)
Number of subjects: 22
Study 7916157 — intervention group
Group type: COMPARATOR
Intervention: Low-dose neuroleptic treatment (375 mg equivalent of chlorpromazine or below)
Number of subjects: 22
Study 3282336 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir 200 mg taken orally three times daily for six months
Number of subjects: 47
Study 3282336 — intervention group
Group type: COMPARATOR
Intervention: Placebo taken orally three times daily for six months
Number of subjects: 47
Study 3282336 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir and placebo
Number of subjects: 47
Study 31912241 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Analog Scale (VAS) ratings
Number of subjects: 33
Study 31912241 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-point ordinal scale ratings
Number of subjects: 33
Study 31177978 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led, caregiver-delivered stroke rehabilitation model, including in-hospital education and training, supported by a smartphone application, with 3 postdischarge support calls.
Number of subjects: 246
Study 31177978 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 246
Study 27923612 — intervention group
Group type: COMPARATOR
Intervention: Kidney Transplant Fast Track (KTFT) evaluation process
Number of subjects: 0
Study 27923612 — intervention group
Group type: EXPERIMENTAL
Intervention: TALK intervention (Talking About Live Kidney Donation)
Number of subjects: 0
Study 27923612 — intervention group
Group type: COMPARATOR
Intervention: Streamlined and coordinated-care evaluation experience
Number of subjects: 0
Study 24853643 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 50,000 IU with 0 g fat (Group 1)
Number of subjects: 64
Study 24853643 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 50,000 IU with 15 g fat (Group 2)
Number of subjects: 64
Study 24853643 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 50,000 IU with 30 g fat (Group 3)
Number of subjects: 64
Study 24853643 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group 4)
Number of subjects: 64